Indian Pharmaceutical Firms Unveil Affordable Semaglutide Injections for Diabetes Management
Synopsis
Three Indian pharmaceutical companies have launched affordable generic semaglutide injections following the expiration of the drug's patent. This innovative approach aims to provide accessible treatment options for Type 2 diabetes and obesity, marking a significant advancement in healthcare affordability.
Key Takeaways
Three Indian companies have launched generic semaglutide injections.
Affordable treatment options for Type 2 diabetes and obesity are now available.
The injections follow the expiration of the drug's patent.
Prices range from Rs 750 to Rs 4,200 monthly.
India ranks third globally in medicine production.
New Delhi, March 21 (NationPress) In a significant development for diabetes and obesity management, three Indian pharmaceutical firms have introduced generic formulations of semaglutide injections following the expiration of the drug's patent. This move aims to provide affordable alternatives for patients coping with Type 2 diabetes and obesity.
The companies involved—Sun Pharma, Zydus Lifesciences, and Dr. Reddy's Laboratories—unveiled their products a day after Natco Pharma, based in Hyderabad, launched its own generic semaglutide injection in India, priced at Rs 1,290 monthly.
Sun Pharma has branded its semaglutide as Noveltreat and Sematrinity. Noveltreat is aimed at chronic weight management and is available in five different dose strengths. In contrast, Sematrinity targets patients with Type 2 diabetes that is not adequately controlled and comes in two dose strengths.
The cost for the weekly therapy for Noveltreat ranges from approximately Rs 900 to Rs 2,000, while for Sematrinity, it is between Rs 750 to Rs 1,300, as reported.
Zydus Lifesciences has introduced its semaglutide injection in a convenient reusable multi-dose pen device, marketed under the names SEMAGLYN, MASHEMA, and ALTERME. This product is aimed at both Type 2 diabetes and obesity, with an estimated average monthly treatment cost of Rs 2,200.
Dr. Reddy’s Laboratories has launched Obeda, touted as India’s first DCGI-approved generic semaglutide specifically for Type 2 diabetes. This drug is available in 2 mg and 4 mg pre-filled disposable pens, intended for weekly use, priced at Rs 4,200 monthly for both strengths.
Semaglutide is classified as a GLP-1 receptor agonist, known for its proven efficacy in enhancing glycaemic control and aiding in weight management globally.
As a backdrop to this development, India's pharmaceutical exports have seen a growth of 9.4% in 2024–25, reaching $30.47 billion. The industry is poised for double-digit growth in 2026–27, bolstered by robust government support, according to the Ministry of Commerce and Industry.
The overall pharmaceutical sector, currently valued at around $60 billion, is projected to reach $130 billion by 2030, as noted by the ministry.
India ranks third worldwide in terms of medicine production volume and exports its pharmaceutical products to over 200 countries.
Point of View
The launch of generic semaglutide injections by Indian pharmaceutical companies represents a crucial step in making diabetes and obesity management more affordable. With increasing healthcare costs, these developments could significantly improve access to treatment for millions of patients across the country.
NationPress
10 May 2026
Frequently Asked Questions
What is semaglutide?
Semaglutide is a medication classified as a GLP-1 receptor agonist, used to improve glycaemic control in patients with Type 2 diabetes and assist with weight management.
Which companies have launched generic semaglutide?
The companies that have launched generic semaglutide are Sun Pharma, Zydus Lifesciences, and Dr. Reddy's Laboratories.
What are the price ranges for these new semaglutide injections?
The prices for the new semaglutide injections range from Rs 750 to Rs 4,200 per month, depending on the brand and dosage.
How does semaglutide help in diabetes management?
Semaglutide helps improve glycaemic control and supports weight loss, which can be beneficial for patients with Type 2 diabetes.
What is the projected growth of India's pharmaceutical sector?
India's pharmaceutical sector is currently valued at around $60 billion and is projected to grow to $130 billion by 2030.
